Companion Diagnostics Market Size Projected to Reach $19.58 billion by 2034 | 12.8%

The global companion diagnostics market size reached USD 8.98 billion in 2025 and is anticipated to grow from USD 10.09 billion in 2026 to USD 25.58 billion by 2034, expanding at a CAGR of 12.33% over the forecast period from 2026 to 2034.

Companion diagnostics play a significant role in advanced healthcare as it helps to target the identification of biomarkers and reduce the cost and time of clinical trials and marketing the drug product. Additionally, the U.S. Food and Drug Administration (FDA) is actively working to provide a defined structure for the development of companion diagnostics, further driving the market growth. As per the GLOBOCAN 2018, in 2018, about 18.1 million new cancer cases and 9.6 million cancer deaths were recorded across the globe. Thus, the growing prevalence of cancer cases prompts the need for effective companion diagnostics.

Increasing government initiatives for the development of companion diagnostics and therapies fosters the market growth. For instance, the U.S. government announced plans to launch Precision Medicine Initiative in 2015, which has led to powerful new discoveries and several new treatments that are developed for specific characteristics, such as person’s genetic makeup.

Key Highlights

• The global companion diagnostics market size reached USD 8.98 billion in 2025 and is anticipated to grow from USD 10.09 billion in 2026 to USD 25.58 billion by 2034, expanding at a CAGR of 12.33% over the forecast period from 2026 to 2034.
• The molecular diagnostics segment holds the highest market share
• The oncology segment dominates the market on account of growing collaboration activities by market players for the development of effective companion diagnostics solutions  
• Geographically, North America dominates the companion diagnostics market owing to the presence of well-established manufacturers and growing market authorization for diagnostic products

Market Segments

1. By Technology
   1. Polymerase Chain Reaction (PCR) 
   2. Next-generation Sequencing (NGS)
   3. Immunohistochemistry
   4. In Situ Hybridization
   5. Others
2. By Indication
   1. Oncology
   2. Autoimmune Diseases
   3. Cardiovascular Diseases
   4. Central Nervous System Disorders
   5. Virology Diseases
   6. Others